發(fā)布時(shí)間：2018-05-23 11:42

  本文選題：新藥臨床試驗(yàn) + 安慰劑對(duì)照　； 參考：《中華中醫(yī)藥雜志》2015年02期

【摘要】：對(duì)一項(xiàng)新藥臨床試驗(yàn)進(jìn)行回顧性研究發(fā)現(xiàn),知情同意導(dǎo)致反安慰劑效應(yīng),嚴(yán)重干擾療效評(píng)估;功能性指標(biāo)更易受反安慰劑效應(yīng)的干擾,而客觀指標(biāo)則較為穩(wěn)定。建議嚴(yán)格選擇應(yīng)用安慰劑的適應(yīng)癥、使用客觀指標(biāo)判定療效、采用基礎(chǔ)治療與加載試驗(yàn)、謹(jǐn)慎納入人格缺陷者、暫時(shí)隱瞞等應(yīng)對(duì)反安慰劑效應(yīng)。
[Abstract]:A retrospective study of a new drug clinical trial found that informed consent resulted in anti-placebo effect, which seriously interfered with the evaluation of efficacy; the functional index was more susceptible to anti-placebo effect, while the objective index was more stable. It is suggested that the indications of placebo should be strictly selected, objective indexes should be used to judge the curative effect, basic treatment and loading test should be adopted, personality defect should be carefully included, and temporary concealment should be used to deal with the antiplacebo effect.
【作者單位】： 商洛學(xué)院;商洛職業(yè)技術(shù)學(xué)院;陜西天方科技有限責(zé)任公司;陜西中醫(yī)學(xué)院;
【分類號(hào)】：R969.4

【參考文獻(xiàn)】

相關(guān)期刊論文 前3條

1 倪青;姜山;肖月星;馮興中;李建民;朱章志;劉敏;魏愛生;蘇秀海;高天舒;胡筱娟;袁志敏;張效科;;芪藥消渴膠囊治療早期糖尿病腎病多中心、隨機(jī)、雙盲、安慰劑對(duì)照臨床觀察[J];中華中醫(yī)藥雜志;2013年08期

2 葉少劍;;臨床工作中應(yīng)重視“安慰劑”效應(yīng)[J];醫(yī)學(xué)與哲學(xué)(臨床決策論壇版);2009年09期

3 武振宇;賈慧s，

本文編號(hào)：1924581